ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance

References

• Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352):eaan2507. doi:10.1126/science.aan2507.
   PubMed Web of Science ®Google Scholar
• Buchanan PC, Boylan KLM, Walcheck B, Heinze R, Geller MA, Argenta PA, Skubitz APN. Ectodomain shedding of the cell adhesion molecule nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17. J Biol Chem. 2017;292:6339–11. doi:10.1074/jbc.M116.746859.
   PubMed Web of Science ®Google Scholar
• Ni -S-S, Zhang J, Zhao W-L, Dong X-C, Wang J-L. ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival. Tumor Biol. 2013;34:1813–1818. doi:10.1007/s13277-013-0721-3.
   PubMedGoogle Scholar
• Wang -Y-Y, Ye Z-Y, Li L, Zhao Z-S, Shao Q-S, Tao H-Q. ADAM 10 is associated with gastric cancer progression and prognosis of patients. J Surg Oncol. 2011;103:116–123. doi:10.1002/jso.21781.
   PubMed Web of Science ®Google Scholar
• You B, Shan Y, Shi S, Li X, You Y. Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma. Cancer Sci. 2015;106:1506–1514. doi:10.1111/cas.12800.
   PubMed Web of Science ®Google Scholar
• Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li J-L, et al. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget. 2014;5:6633–6646. doi:10.18632/oncotarget.v5i16.
   PubMedGoogle Scholar
• Van Schaeybroeck S, Kalimutho M, Dunne P, Carson R, Allen W, Jithesh P, Redmond K, Sasazuki T, Shirasawa S, Blayney J, et al. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep. 2014;7:1940–1955. doi:10.1016/j.celrep.2014.05.032.
   PubMed Web of Science ®Google Scholar
• Yang C, Jiang F, Xu F, Jiang G. ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma. Tumor Biol. 2012;33:1535–1541. doi:10.1007/s13277-012-0405-4.
   PubMedGoogle Scholar
• Sharma A, Bender S, Zimmermann M, Riesterer O, Broggini-Tenzer A, Pruschy MN. Secretome signature identifies ADAM17 as novel target for radiosensitization of non-small cell lung cancer. Clin. Cancer Res. 2016;22:4428–4439. doi:10.1158/1078-0432.CCR-15-2449.
   PubMed Web of Science ®Google Scholar
• Reiss K, Ludwig A, Saftig P. Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol Ther. 2006;111:985–1006. doi:10.1016/j.pharmthera.2006.02.009.
   PubMed Web of Science ®Google Scholar
• Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA, Israël A, et al. A novel proteolytic cleavage involved in notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell. 2000;5:207–216. doi:10.1016/S1097-2765(00)80417-7.
   PubMed Web of Science ®Google Scholar
• Sahin U, Blobel CP. Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17. FEBS Lett. 2007;581:41–44. doi:10.1016/j.febslet.2006.11.074.
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee H-G, Steinle A. Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 2008;68:6368–6376. doi:10.1158/0008-5472.CAN-07-6768.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 2002;8:793. doi:10.1038/nm730.
   PubMed Web of Science ®Google Scholar
• Dronca RS, Liu X, Harrington SM, Chen L, Cao S, Kottschade LA, McWilliams RR, Block MS, Nevala WK, Thompson MA, et al. T cell bim levels reflect responses to anti–PD-1 cancer therapy. JCI Insight. 2016;1. doi:10.1172/jci.insight.86014.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690.
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Long GV, Scolyer RA, Teng MWL, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71–81. doi:10.1016/j.ctrv.2016.11.007.
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847–856. doi:10.1158/1535-7163.MCT-14-0983.
   PubMed Web of Science ®Google Scholar
• Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, Leibovich B, Blute ML, Dong H, Kwon ED, et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. Clin Cancer Res. April. 2011;1:1915–1923. doi:10.1158/1078-0432.CCR-10-0250.
   Google Scholar
• Gomes J, Lucien F, Cooper T, Kim Y, Williams K, Liao X, Kaufman L, Lagugné-Labarthet F, Kenyon O, Boysen J, et al. Analytical considerations in nanoscale flow cytometry of extracellular vesicles to achieve data linearity. Thromb Haemost. 2018;118:1612–1624. doi:10.1055/s-0038-1668544.
   PubMed Web of Science ®Google Scholar
• Qu P, Crowley J. Fit a grey-zone model with survival data. 2015.
   Google Scholar
• Mahoney KM, Shukla SA, Patsoukis N, Chaudhri A, Browne EP, Arazi A, Eisenhaure TM, Pendergraft WF, Hua P, Pham HC, et al. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol Immunother. 2018;1–12. doi:10.1007/s00262-018-2282-1.
   Web of Science ®Google Scholar
• Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann. Oncol. 2016;27:147–153. doi:10.1093/annonc/mdv489.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Murphy SJ, Peikert T, Yi ES, Vasmatzis G, Wigle DA, Aubry MC. Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer. Clin Cancer Res. 2016;22:2177–2182. doi:10.1158/1078-0432.CCR-15-2246.
   PubMed Web of Science ®Google Scholar
• Mansfield A, Dong H. Implications of programmed cell death 1 ligand 1 heterogeneity in the selection of patients with non-small cell lung cancer to receive immunotherapy. Clin Pharmacol Ther. 2016;100:220–222. doi:10.1002/cpt.360.
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–918. doi:10.1016/S1470-2045(15)00083-2.
   PubMed Web of Science ®Google Scholar
• Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560:382–386. doi:10.1038/s41586-018-0392-8.
   PubMed Web of Science ®Google Scholar
• Stoeck A, Keller S, Riedle S, Sanderson M, Runz S, Le Naour F, Gutwein P, Ludwig A, Rubinstein E, Altevogt P, et al. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem. J. 2006;393:609–618. doi:10.1042/BJ20051013.
   PubMed Web of Science ®Google Scholar
• Finkelmeier F, Canli O, Tal A, Pleli T, Trojan J, Schmidt M, Piiper A, Kronenberger B, Zeuzem S, Greten FR, et al. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Z Gastroenterol. 2015;53:A4_19. doi:10.1055/s-00000094.
   PubMedGoogle Scholar
• Ha H, Nam A-R, Bang J-H, Park J-E, Kim T-Y, Lee K-H, Han S-W, Im S-A, Kim T-Y, Bang Y-J, et al. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget. 2016;7:76604–76612. doi:10.18632/oncotarget.v7i47.
   PubMedGoogle Scholar
• Okuma Y, Hosomi Y, Nakahara Y, Watanabe K, Sagawa Y, Homma S. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer. 2017;104:1–6. doi:10.1016/j.lungcan.2016.11.023.
   PubMed Web of Science ®Google Scholar
• Zhang J, Gao J, Li Y, Nie J, Dai L, Hu W, Chen X, Han J, Ma X, Tian G, et al. Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. Thorac Cancer. 2015;6:534–538. doi:10.1111/tca.2015.6.issue-4.
   PubMed Web of Science ®Google Scholar
• Costantini A, Julie C, Dumenil C, Hélias-Rodzewicz Z, Tisserand J, Dumoulin J, Giraud V, Labrune S, Chinet T, Emile J-F, et al. Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. Oncoimmunology. 2018;e1452581. doi:10.1080/2162402X.2018.1452581.
   PubMed Web of Science ®Google Scholar
• Dronca R, Leontovich A, Harrington S, Jegapragasan M, Kottschade L, Nevala W, Enninga E, Markovic S, Dong H. Soluble PD-L1 (sPD-L1) is associated with decreased survival in metastatic melanoma. Pigment Cell Melanoma Res. 2015;28:768–769.
   Google Scholar
• Dronca RS, Mansfield AS, Liu X, Harrington S, Enninga EA, Kottschade LA, Koo CW, McWilliams RR, Block MS, Nevala WK, et al. Bim and soluble PD-L1 (sPD-L1) as predictive biomarkers of response to anti-PD-1 therapy in patients with melanoma and lung carcinoma. J. Clin. Oncol. 2017;35:11534. doi:10.1200/JCO.2017.35.15_suppl.11534.
   Google Scholar
• Wang L, Wang H, Chen H, Wang W-D, Chen X-Q, Geng Q-R, Xia Z-J, Lu Y. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget. 2015;6:41228–41236. doi:10.18632/oncotarget.v6i38.
   PubMedGoogle Scholar
• Wang H, Wang L, Liu W-J, Xia Z-J, Huang H-Q, Jiang W-Q, Li Z-M, Lu Y. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients. Oncotarget. 2016;7:33035–33045. doi:10.18632/oncotarget.8847.
   PubMedGoogle Scholar
• Sideras K, de Man RA, Harrington SM, Polak WG, Zhou G, Schutz HM, Pedroza-Gonzalez A, Biermann K, Mancham S, Hansen BE, et al. Circulating levels of PD-L1 and galectin-9 are associated with patient survival in surgically treated hepatocellular carcinoma independent of their intra-tumoral expression levels. Sci Rep. 2019;9:10677. doi:10.1038/s41598-019-47235-z.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Bu Z, Liu X, Zhang L, Li Z, Wu A, Wu X, Cheng X, Xing X, Du H, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res. 2014;26:104–111. doi:10.3978/j..1000-9604.2014.02.08.
   PubMed Web of Science ®Google Scholar
• Blaydon DC, Biancheri P, Di W-L, Plagnol V, Cabral RM, Brooke MA, van Heel DA, Ruschendorf F, Toynbee M, Walne A, et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J Med. 2011;365:1502–1508. doi:10.1056/NEJMoa1100721.
   PubMed Web of Science ®Google Scholar